A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
The purpose of this study is to describe the use of teclistamab in the treatment of patients with RRMM outside of clinical trials.
- EligibilityCriteria: Inclusion Criteria:  Have a documented diagnosis of multiple myeloma Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment Received at least one dose of teclistamab Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements  Exclusion Criteria:  Received teclistamab as part of an interventional clinical trial - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Study population include patients who have initiated the treatment with T-cell redirectors outside of a clinical trial setting. - SamplingMethod: Non-Probability Sample